10.86
前日終値:
$12.12
開ける:
$10.99
24時間の取引高:
382.31K
Relative Volume:
1.80
時価総額:
$1.61B
収益:
$7.50M
当期純損益:
$-81.89M
株価収益率:
0.2048
EPS:
53.0176
ネットキャッシュフロー:
$-63.58M
1週間 パフォーマンス:
+2.94%
1か月 パフォーマンス:
+4.62%
6か月 パフォーマンス:
-47.31%
1年 パフォーマンス:
+68.37%
Mesoblast Ltd Adr Stock (MESO) Company Profile
MESO を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
MESO
Mesoblast Ltd Adr
|
10.86 | 1.61B | 7.50M | -81.89M | -63.58M | 53.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-23 | ダウングレード | Jefferies | Buy → Hold |
2024-09-24 | アップグレード | Maxim Group | Hold → Buy |
2024-08-29 | アップグレード | Jefferies | Hold → Buy |
2024-07-23 | アップグレード | Piper Sandler | Neutral → Overweight |
2023-08-31 | アップグレード | Jefferies | Hold → Buy |
2023-08-07 | ダウングレード | Maxim Group | Buy → Hold |
2023-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
2023-08-04 | ダウングレード | William Blair | Outperform → Mkt Perform |
2023-03-09 | 開始されました | William Blair | Outperform |
2022-12-06 | ダウングレード | Jefferies | Buy → Hold |
2022-09-06 | 開始されました | Piper Sandler | Overweight |
2021-04-07 | アップグレード | Maxim Group | Hold → Buy |
2020-12-22 | ダウングレード | Maxim Group | Buy → Hold |
2020-12-04 | ダウングレード | Chardan Capital Markets | Neutral → Sell |
2020-10-22 | 開始されました | RBC Capital Mkts | Sector Perform |
2020-08-14 | 繰り返されました | Maxim Group | Buy |
2020-05-28 | 繰り返されました | H.C. Wainwright | Buy |
2019-01-31 | 再開されました | H.C. Wainwright | Buy |
2018-03-22 | ダウングレード | Credit Suisse | Neutral → Underperform |
2018-02-28 | 繰り返されました | Cantor Fitzgerald | Buy |
2017-08-31 | 開始されました | Oppenheimer | Outperform |
2017-06-08 | 開始されました | Cantor Fitzgerald | Buy |
すべてを表示
Mesoblast Ltd Adr (MESO) 最新ニュース
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD - GlobeNewswire Inc.
All Markets & Instruments Available to Trade - Capital.com
Mesoblast (ASX:MSB) Secures Medicaid Agreement for Ryoncil® - thecapitalclub.com.au
UPDATED: Your guide to February Reporting Season 2020 - Morningstar.com.au
21 Best-Performing Small-Cap Stocks for March 2025 - NerdWallet
Why Mesoblast Ltd ADR (NASDAQ: MESO) Is Worth Including On Your Watchlist - Marketing Sentinel
The 98.76% Simple Moving Average of Mesoblast Ltd ADR’s (MESO) Stock in the Past 200 Days - The News Heater
Mesoblast Ltd ADR (NASDAQ:MESO) Shares Are Up 10.24 Percent In A Week – But Can The Gains Continue? - Marketing Sentinel
ASX Lunch Wrap: ASX and gold reset record highs; but Origin cuts its LNG forecast - Stockhead
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
Mesoblast Limited Initiates Trading Halt Pending Financing Announcement - TipRanks
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
MESO Stock Surges 80% In A Month After FDA Approval Of GVHD Drug - Barchart
Mesoblast (NASDAQ:MESO) Shares Gap UpWhat's Next? - MarketBeat
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
What Analysts Think About TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP)’s Potential Raise - Stocks Register
NIO Inc ADR (NYSE: NIO) Stock Forecast: Could Pass $8 In A Year - Stocks Register
If You Don’t Buy Safe Pro Group Inc (NASDAQ: SPAI) Now, You’ll Regret It Later - Stocks Register
Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register
Mesoblast Stock Soars to 52-Week High, Hits $19.15 - Investing.com
Here’s Why Lineage Cell Therapeutics Inc (AMEX: LCTX) Is An Attractive Investment Right Now - Stocks Register
No Stopping Editas Medicine Inc (NASDAQ: EDIT)’s Stock Plunged? - Stocks Register
What Do Analysts Think About Therealreal Inc’s (NASDAQ:REAL) Future? - Stocks Register
What Awaits These 4 Biotech Stocks That More Than Doubled In 2024 - Barchart
Mesoblast shares downgraded to hold by Jefferies By Investing.com - Investing.com South Africa
Why the Mesoblast share price is diving 18% after an FDA win - The Motley Fool Australia
Mesoblast share price rockets 30% on big US FDA news - The Motley Fool Australia
Mesoblast stock soars to 52-week high, hits $12.21 - Investing.com
Mesoblast Stock Soars to 52-Week High, Hits $12.19 - Investing.com
Mesoblast stock soars to 52-week high, hits $11.1 - Investing.com
JPMorgan Takes Substantial Stake in Mesoblast Ltd - TipRanks
Mesoblast to raise $50m from top shareholder for product launch - Capital Brief
Mesoblast: Rolling The Dice On Cellular Medicines (NASDAQ:MESO) - Seeking Alpha
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
11 Best ASX Stocks To Buy Now - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Australia stocks higher at close of trade; S&P/ASX 200 up 0.43% - Investing.com
Philip R. Krause, M.D., Former FDA Deputy Chief For Vaccines, Joins Mesoblast Board - Barchart
ASX dives as Trump tests COVID positive - The Australian
The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal - Yahoo Finance
Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology - streetwisereports.com
6 ASX BioTechs Trading on the NASDAQ - TheBull.com.au
Mesoblast Ltd Adr (MESO) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):